<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455741</url>
  </required_header>
  <id_info>
    <org_study_id>2000P-002496</org_study_id>
    <secondary_id>R01AG013241</secondary_id>
    <nct_id>NCT00455741</nct_id>
  </id_info>
  <brief_title>Postmenopausal Women Estrogen and Progesterone Infusion</brief_title>
  <official_title>Effect of Age on Gonadotropin Responses to Short-Term Negative and Positive Feedback Effects of Gonadal Steroids Using PET Scanning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to study the effects of aging, estrogen and progesterone on the
      brain. Specifically, we want to look at how the hypothalamus and pituitary (two small glands
      in the brain) respond to estrogen. The pituitary gland is controlled by the hypothalamus. The
      hypothalamus secretes GnRH (Gonadotropin-Releasing Hormone) that signals the pituitary to
      secrete the reproductive hormones, LH (Luteinizing Hormone) and FSH (Follicle Stimulating
      Hormone). These hormones act on the ovaries and signal the ovaries to produce estrogen and
      progesterone. Estrogen in the bloodstream then acts on the brain to modulate this system with
      changes in LH and FSH. Early changes associated with low levels of estrogen are inhibitory
      (estrogen negative feedback) while higher levels of estrogen (such as those present when a
      follicle in the ovary is ready to ovulate) stimulate LH to cause ovulation (positive
      feedback). This study will determine: 1) hypothalamic and pituitary levels of glucose uptake
      (as a measure of brain metabolic activity) at baseline and in association with estrogen
      negative feedback on LH (24 hr) and estrogen positive feedback on LH (72 hr); and 2) the
      effect of aging on estrogen feedback on LH, assessing negative feedback (nadir ~ 24 hr) and
      positive feedback (peak between 72 and 96 hr).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The transition to menopause is characterized by a decline in the numbers of functional
      ovarian follicles followed by a decrease in levels of inhibin A and B and complex changes in
      estradiol, which include an initial increase followed by an inevitable decrease. Therefore,
      there are dynamic changes in the hypothalamic-pituitary feedback from the aging ovary, prior
      to the ultimate loss of feedback that occurs with the complete cessation of ovarian function.
      While there is ample evidence that the loss of ovarian function is a major contributor to the
      menopause, there is evidence from animal models that primary age-related neuroendocrine
      changes may also contribute to reproductive aging. Specifically, there is evidence for
      changes in the hypothalamic and pituitary responses to estrogen negative and positive
      feedback. An understanding of the age-related changes in the physiology of the hypothalamic
      and pituitary responsiveness to gonadal steroid feedback is critical in determining whether
      hypothalamic and pituitary changes per se contribute to the menopause and the impact of the
      loss of reproductive function on the brain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">August 22, 2015</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Estradiol and progesterone infusion to assess negative and positive feedback on the hypothalamus and pituitary in young and older postmenopausal women.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Aging on Estrogen Negative Feedback on LH</measure>
    <time_frame>Baseline at 0 time before infusion, nadir occurred between 8 and 60 hr (mean 24 hr)</time_frame>
    <description>Difference between baseline LH (average of 3 samples drawn 15 min apart) and nadir LH based on a 3-point moving average of blood samples drawn every 4 hours over 120 hr, expressed as a percent of baseline (% baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Aging on Estrogen Positive Feedback on LH</measure>
    <time_frame>Onset of surge (average of 61 hr from beginnning of infusion until the end of the study (120 hr)</time_frame>
    <description>LH area under the curve in response to estrogen positive feedback. Area under the curve was calculated from blood samples drawn every 4 hours from the onset of positive feedback until the end of the study (120 min). The onset of positive feedback is defined as the time when LH first exceeds mean + 2SD of the previous three time points and shows a sustained rise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Negative Feedback</measure>
    <time_frame>Baseline vs 24 hr after the onset of steroid infusion</time_frame>
    <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Negative Feedback</measure>
    <time_frame>0 vs 24 hr</time_frame>
    <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Positive Feedback</measure>
    <time_frame>24 hr vs 72 hr</time_frame>
    <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Positive Feedback</measure>
    <time_frame>24 vs 72 hr</time_frame>
    <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Postmenopause</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Young postmenopausal women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older postmenopausal women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol infusion</intervention_name>
    <description>Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.</description>
    <arm_group_label>Young postmenopausal women</arm_group_label>
    <arm_group_label>Older postmenopausal women</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone infusion</intervention_name>
    <description>Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
    <arm_group_label>Young postmenopausal women</arm_group_label>
    <arm_group_label>Older postmenopausal women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        postmenopausal women young (age 45-55) or old (age 70-80) History of natural menopause
        defined by the absence of menses for at least 12 months (or history of surgical menopause
        defined as bilateral oophorectomy) Normal TSH, PRL and CBC, and Factor V activity Normal
        BUN and Creatinine (&lt; 2 times the upper limit of normal) BMI between 18 to 30 kg/m2 An
        increased FSH measured at the screening visit will be consistent with menopause. If the
        initial determination is low, a repeat sample may be drawn.

        Exclusion criteria:

        Hormonal medication or herbal supplements and/or over the counter menopause therapy in the
        2 months prior to study Any absolute contraindications to the use of physiologic
        replacement doses of estrogen and/or progesterone History of coronary artery disease
        Medications thought to act centrally on the GnRH pulse generator History of breast cancer
        or blood clots Smoking more than 10 cigarettes/day Prior history of allergic reaction to
        any dyes used with x-rays or scans and/ or any other contraindications to PET scans No
        metal implants, pacemakers, aneurysm clips, implanted hearing aids and/or any other
        contraindications to MRI scan
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Hall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shaw ND, Srouji SS, Histed SN, Hall JE. Differential effects of aging on estrogen negative and positive feedback. Am J Physiol Endocrinol Metab. 2011 Aug;301(2):E351-5. doi: 10.1152/ajpendo.00150.2011. Epub 2011 May 10.</citation>
    <PMID>21558550</PMID>
  </results_reference>
  <results_reference>
    <citation>Ottowitz WE, Derro D, Dougherty DD, Lindquist MA, Fischman AJ, Hall JE. FDG-PET analysis of amygdalar-cortical network covariance during pre- versus post-menopausal estrogen levels: potential relevance to resting state networks, mood, and cognition. Neuro Endocrinol Lett. 2008 Aug;29(4):467-74.</citation>
    <PMID>18766152</PMID>
  </results_reference>
  <results_reference>
    <citation>Ottowitz WE, Dougherty DD, Fischman AJ, Hall JE. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography demonstration of estrogen negative and positive feedback on luteinizing hormone secretion in women. J Clin Endocrinol Metab. 2008 Aug;93(8):3208-14. doi: 10.1210/jc.2008-0203. Epub 2008 Jun 3.</citation>
    <PMID>18522979</PMID>
  </results_reference>
  <results_reference>
    <citation>Ottowitz WE, Siedlecki KL, Lindquist MA, Dougherty DD, Fischman AJ, Hall JE. Evaluation of prefrontal-hippocampal effective connectivity following 24 hours of estrogen infusion: an FDG-PET study. Psychoneuroendocrinology. 2008 Nov;33(10):1419-25. doi: 10.1016/j.psyneuen.2008.09.013. Epub 2008 Oct 31.</citation>
    <PMID>18977091</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <results_first_submitted>April 18, 2014</results_first_submitted>
  <results_first_submitted_qc>April 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2018</results_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet E. Hall, MD</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>menopause</keyword>
  <keyword>estrogen</keyword>
  <keyword>progesterone</keyword>
  <keyword>hormone replacement</keyword>
  <keyword>aging</keyword>
  <keyword>PET</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Requests for sharing coded results without patient identifiers can be made directly to the PI.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>36 subjects consented; 6 failed screening, 2 decided not to participate.</recruitment_details>
      <pre_assignment_details>1 subject terminated during study (hemoglobin drop) for a total of 24 completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Younger PMW</title>
          <description>Postmenopausal women (PMW) ages 45-55 receiving the following hormone infusions.
Estradiol infusion:
Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr, and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion:
Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
        </group>
        <group group_id="P2">
          <title>Older PMW</title>
          <description>Postmenopausal women (PMW) ages 70-80 receiving the following hormone infusions.
Estradiol infusion:
Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr, and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion:
Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects were healthy and had experienced their last menstrual period 18 mo previously. Subjects were not on any medications known to interact with the neuroendocrine reproductive axis, including over-the-counter medications or herbal remedies. Factor V Leiden mutations were absent in all patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Younger PMW</title>
          <description>Postmenopausal women (PMW) ages 45-55 receiving the following hormone infusions.
Estradiol infusion:
Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr, and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion:
Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
        </group>
        <group group_id="B2">
          <title>Older PMW</title>
          <description>Postmenopausal women (PMW) ages 70-80 receiving the following hormone infusions.
Estradiol infusion:
Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr, and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion:
Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="3.8"/>
                    <measurement group_id="B2" value="75.2" spread="3.6"/>
                    <measurement group_id="B3" value="61.3" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Aging on Estrogen Negative Feedback on LH</title>
        <description>Difference between baseline LH (average of 3 samples drawn 15 min apart) and nadir LH based on a 3-point moving average of blood samples drawn every 4 hours over 120 hr, expressed as a percent of baseline (% baseline).</description>
        <time_frame>Baseline at 0 time before infusion, nadir occurred between 8 and 60 hr (mean 24 hr)</time_frame>
        <population>NOTE: 2 older and 2 younger postmenopausal women excluded from this analysis as estradiol levels exceeded physiological exposure levels</population>
        <group_list>
          <group group_id="O1">
            <title>Younger PMW</title>
            <description>Postmenopausal women (PMW) ages 45-55 receiving the following hormone infusions.
Estradiol infusion:
Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr, and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion:
Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
          </group>
          <group group_id="O2">
            <title>Older PMW</title>
            <description>Postmenopausal women (PMW) ages 70-80 receiving the following hormone infusions.
Estradiol infusion:
Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr, and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion:
Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Aging on Estrogen Negative Feedback on LH</title>
          <description>Difference between baseline LH (average of 3 samples drawn 15 min apart) and nadir LH based on a 3-point moving average of blood samples drawn every 4 hours over 120 hr, expressed as a percent of baseline (% baseline).</description>
          <population>NOTE: 2 older and 2 younger postmenopausal women excluded from this analysis as estradiol levels exceeded physiological exposure levels</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.8" spread="3.0"/>
                    <measurement group_id="O2" value="-53.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>effect of age on estrogen negative feedback ( nadir LH as % of baseline LH)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>positive feedback</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.03</p_value>
            <p_value_desc>a priori threshold for significance is p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Aging on Estrogen Positive Feedback on LH</title>
        <description>LH area under the curve in response to estrogen positive feedback. Area under the curve was calculated from blood samples drawn every 4 hours from the onset of positive feedback until the end of the study (120 min). The onset of positive feedback is defined as the time when LH first exceeds mean + 2SD of the previous three time points and shows a sustained rise.</description>
        <time_frame>Onset of surge (average of 61 hr from beginnning of infusion until the end of the study (120 hr)</time_frame>
        <population>NOTE: 2 older and 2 younger postmenopausal women excluded from this analysis as estradiol levels exceeded physiological exposure levels</population>
        <group_list>
          <group group_id="O1">
            <title>Young Postmenopausal Women</title>
            <description>Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
Estradiol infusion: Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion: Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
          </group>
          <group group_id="O2">
            <title>Older Postmenopausal Women</title>
            <description>Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..
Estradiol infusion: Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion: Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Aging on Estrogen Positive Feedback on LH</title>
          <description>LH area under the curve in response to estrogen positive feedback. Area under the curve was calculated from blood samples drawn every 4 hours from the onset of positive feedback until the end of the study (120 min). The onset of positive feedback is defined as the time when LH first exceeds mean + 2SD of the previous three time points and shows a sustained rise.</description>
          <population>NOTE: 2 older and 2 younger postmenopausal women excluded from this analysis as estradiol levels exceeded physiological exposure levels</population>
          <units>IU*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4544.6" spread="636.3"/>
                    <measurement group_id="O2" value="2885.5" spread="316.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.03</p_value>
            <p_value_desc>a priori significance level p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Negative Feedback</title>
        <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
        <time_frame>Baseline vs 24 hr after the onset of steroid infusion</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline Pituitary</title>
            <description>18 FDG uptake at the pituitary at baseline</description>
          </group>
          <group group_id="O2">
            <title>Negative Feedback Pituitary</title>
            <description>18 FDG uptake at the pituitary at 24 hr associated with estrogen induced negative feedback on LH</description>
          </group>
        </group_list>
        <measure>
          <title>18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Negative Feedback</title>
          <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
          <population>postmenopausal women</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="4.5"/>
                    <measurement group_id="O2" value="48.4" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>threshold for significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Negative Feedback</title>
        <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
        <time_frame>0 vs 24 hr</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline Hypothalamus</title>
            <description>18 FDG uptake at the hypothalamus at baseline</description>
          </group>
          <group group_id="O2">
            <title>Negative Feedback Hypothalamus</title>
            <description>18 FDG uptake at the at the hypothalamus at 24 hr associated with estrogen induced negative feedback on LH</description>
          </group>
        </group_list>
        <measure>
          <title>18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Negative Feedback</title>
          <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
          <population>postmenopausal women</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" spread="3.3"/>
                    <measurement group_id="O2" value="63.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.02</p_value>
            <p_value_desc>a priori threshold for significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Positive Feedback</title>
        <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
        <time_frame>24 hr vs 72 hr</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>Pituitary at 24 hr</title>
            <description>18 FDG uptake at the pituitary at 24 hr</description>
          </group>
          <group group_id="O2">
            <title>Pituitary at 72 hr</title>
            <description>18 FDG uptake at the pituitary at 72 hr associated with estrogen induced positive feedback on LH</description>
          </group>
        </group_list>
        <measure>
          <title>18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Positive Feedback</title>
          <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
          <population>postmenopausal women</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" spread="4.0"/>
                    <measurement group_id="O2" value="54.3" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Positive Feedback</title>
        <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
        <time_frame>24 vs 72 hr</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>Hypothalamus at 24 hr</title>
            <description>18 FDG uptake at the hypothalamus at 24 hr</description>
          </group>
          <group group_id="O2">
            <title>Hypothalamus 72 hr</title>
            <description>18 FDG uptake at the pituitary at 72 hr associated with estrogen induced positive feedback on LH</description>
          </group>
        </group_list>
        <measure>
          <title>18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Positive Feedback</title>
          <description>Regional cerebral glucose metabolism (rCMRglu) is used as a measure of neuronal metabolic activity and calculated as average uptake (voxels) of 18 flurodeoxyglucose within the region of interest (ROI) and expressed simply as units. Normalized uptake refers to co-registration of the PET with the MRI to provide more accurate anatomic correlates.</description>
          <population>postmenopausal women</population>
          <units>unit</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="2.8"/>
                    <measurement group_id="O2" value="66.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>a priori significance set at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days for each subject; 4 years in total</time_frame>
      <desc>As in clinicaltrials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>Younger PMW</title>
          <description>Postmenopausal women (PMW) ages 45-55 receiving the following hormone infusions.
Estradiol infusion:
Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr, and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion:
Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
        </group>
        <group group_id="E2">
          <title>Older PMW</title>
          <description>Postmenopausal women (PMW) ages 70-80 receiving the following hormone infusions.
Estradiol infusion:
Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr, and 0.2 mcg/kg/hr for 60 hr.
Progesterone infusion:
Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>decrease in hemoglobin below pre-specified level</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vasomotor symptoms</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>mild vasomotor symptoms during estradiol infusion</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>PET scan data addresses hypothalamic vs pituitary sites of negative and positive estrogen feedback on LH, but there was insufficient power to address the effect of aging on these secondary measures..</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Janet E. Hall</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-877-1112</phone>
      <email>hall.janet@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

